Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 3821001 in Healthy Participants
NCT07908004Phase 1Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial comparing BI 3821001 treatment group with Placebo group (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 81 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BI 3821001
Beyond the preview
Go deeper on NCT07908004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908004.